Gynecologic Cancers

Treatment for sexual pain in women who have been affected by cancer is an unmet need in both oncology and gynecology.

In a recent phase III study, the PARP-inhibitor olaparib was shown to improve progression-free survival for patients with BRCA-positive ovarian cancer.

The Society for Gynecologic Oncology (SGO) released a toolkit of case studies and resources on genetic testing for healthcare providers, patients, and their families.

New ASCO guidelines for cervical cancer screening recommend HPV DNA testing.

In a phase III trial, niraparib as maintenance therapy reduced the risk of progression or death by 73% for patients with recurrent ovarian cancer.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

The NOCC is connecting women who have ovarian cancer to others who are experiencing similar struggles.

In the last two decades, global ovarian cancer mortality rates have either levelled or declined.

Michael Birrer, MD, PhD, Harvard Medical School, discusses what he hopes to discover as factors that influence long-term survival in patients and survivors with ovarian cancer.

A study has found that telephone cancer genetic counseling can be just as effective as in-person counseling for women at risk for hereditary breast and ovarian cancer

While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and interval cytoreduction.

What do patients think about being tested for many genes that may impact their hereditary risk for breast or ovarian cancer, beyond the well-known BRCA mutations?

National guidelines recommend that women with a personal history of ovarian cancer be tested for the BRCA mutation. Approximately 1.3% of women will develop ovarian cancer, according to the National Cancer Institute, but that risk increases to an estimated 39% in women with the BRCA1 mutation and 11% to 17% in women who inherit the BRCA2 mutation.

Michael Birrer, MD, PhD, Harvard Medical School, discusses the importance of personalized care for ovarian cancer.

Researchers at the Dana-Farber Cancer Institute are testing a psychoeducational intervention that they hope will offer relief for sexual problems after treatment.

On May 25, 2016, the American Society of Clinical Oncology (ASCO) released evidence-based, resource-stratified global recommendations on the management and palliative care of women diagnosed with invasive cervical cancer.

Resources and information about possible loss of fertility after cancer treatment and preservation measures to prevent infertility are sorely lacking for young women, according to a new study.

Pregnant and diagnosed with cervical cancer at age 27, I chose treatment and my daughter and I survived what experts said would kill us.

Bright Pink's Women's Health Provider Education program is designed to address gaps in knowledge of young women's genetic cancer risk.

The Julie Fund for Women’s Cancers remains single largest philanthropic source of funding for ovarian cancer research at Massachusetts General Hospital.

This survey is open to any woman diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, regardless of whether or not you have had genetic counseling or testing.

For patients with epithelial ovarian cancer, adjuvant hormone therapy (AHT) proved to be safe and reduced the risk of death by 37%, according to findings of a 24-year study recently published in the Journal of Clinical Oncology.

African American women can reduce their risk of developing ovarian cancer by following healthy dietary guidelines, a recent study has found.